{
    "root": "601dfad8-02f7-4696-9fe2-548610338dc9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JANUMET",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SITAGLIPTIN PHOSPHATE",
            "code": "TS63EW8X6F"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "janumet indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . limitations janumet used patients type 1 diabetes mellitus . janumet studied patients history pancreatitis . unknown whether patients history pancreatitis increased risk development pancreatitis using janumet . [ ( 5.2 ) . ]",
    "contraindications": "take janumet orally twice daily meals . ( 2.1 ) individualize janumet basis patient \u2019 current regimen , effectiveness , tolerability . ( 2.1 ) maximum recommended daily dose 100 mg sitagliptin 2000 mg metformin hcl . ( 2.1 ) recommended starting dose patients currently treated metformin 50 mg sitagliptin 500 mg metformin hcl twice daily , gradual dose escalation recommended reduce gastrointestinal side effects associated metformin . ( 2.1 ) starting dose patients already treated metformin provide sitagliptin dosed 50 mg twice daily ( 100 mg total daily dose ) dose metformin already taken . patients taking metformin hcl 850 mg twice daily , recommended starting dose janumet 50 mg sitagliptin 1000 mg metformin hcl twice daily . ( 2.1 ) prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) ( 2.2 ) patients egfr 30 ml/min/1.73 2 . janumet recommended patients egfr 30 less 45 ml/min/1.73 2 . janumet may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.3 )",
    "warningsAndPrecautions": "tablets supplied follows : contents description supplied ndc 50 mg sitagliptin 500 mg metformin hcl light pink , capsule-shaped , film-coated tablets \u201c 575 \u201d debossed one side unit-of-use bottles 60 ndc 0006-0575-61 unit-of-use bottles 180 ndc 0006-0575-62 bulk bottles 1000 ndc 0006-0575-82 50 mg sitagliptin 1000 mg metformin hcl red , capsule-shaped , film-coated tablets \u201c 577 \u201d debossed one side unit-of-use bottles 60 ndc 0006-0577-61 unit-of-use bottles 180 ndc 0006-0577-62 bulk bottles 1000 ndc 0006-0577-82",
    "adverseReactions": "janumet contraindicated patients : severe renal impairment ( egfr 30 ml/min/1.73 m2 ) [ ( 5.1 ) ] . acute chronic metabolic acidosis , including diabetic ketoacidosis . history serious hypersensitivity reaction janumet , sitagliptin , metformin , anaphylaxis angioedema . [ ( 5.7 ) ; ( 6.2 ) . ]",
    "indications_original": "JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\n                  \n                     Limitations of Use\n                  \n                  JANUMET should not be used in patients with type 1 diabetes mellitus.\n                  JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET. [See Warnings and Precautions (5.2).]",
    "contraindications_original": "Take JANUMET orally twice daily with meals. ( 2.1 ) Individualize the dosage of JANUMET on the basis of the patient\u2019s current regimen, effectiveness, and tolerability. ( 2.1 ) The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin HCl. ( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin HCl 850 mg twice daily, the recommended starting dose of JANUMET is 50 mg sitagliptin and 1000 mg metformin HCl twice daily. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) Do not use in patients with eGFR below 30 mL/min/1.73 m 2 . JANUMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . JANUMET may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.3 )",
    "warningsAndPrecautions_original": "Tablets supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           Contents\n                           Description\n\t\t\t\t\t\t\t\t\t\t\t\n                           How Supplied\n                           NDC\n                        \n                     \n                     \n                        \n                           \n\t\t\t\t\t\t\t\t\t\t\t\t50 mg sitagliptin and 500 mg metformin HCl\n\t\t\t\t\t\t\t\t\t\t\t\n                           light pink, capsule-shaped, film-coated tablets with \u201c575\u201d debossed on one side\n                           unit-of-use bottles of 60\n                           NDC 0006-0575-61\n                        \n                        \n                           unit-of-use bottles of 180\n                           NDC 0006-0575-62\n                        \n                        \n                           bulk bottles of 1000\n                           NDC 0006-0575-82\n                        \n                        \n                           \n\t\t\t\t\t\t\t\t\t\t\t\t50 mg sitagliptin and 1000 mg metformin HCl\n\t\t\t\t\t\t\t\t\t\t\t\n                           red, capsule-shaped, film-coated tablets with \u201c577\u201d debossed on one side\n                           unit-of-use bottles of 60\n                           NDC 0006-0577-61\n                        \n                        \n                           unit-of-use bottles of 180\n                           NDC 0006-0577-62\n                        \n                        \n                           bulk bottles of 1000\n                           NDC 0006-0577-82",
    "adverseReactions_original": "JANUMET is contraindicated in patients with:\n                  \n                     Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1)].\n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis.\n                     History of a serious hypersensitivity reaction to JANUMET, sitagliptin, or metformin, such as anaphylaxis or angioedema. [See Warnings and Precautions (5.7); Adverse Reactions (6.2).]"
}